Edgewise Therapeutics, Inc. Earnings Per Share (Basic)
Edgewise Therapeutics, Inc. (EWTX) reported Earnings Per Share (Basic) of -$0.53 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Edgewise Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.53.
- Edgewise Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.46.
- Edgewise Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was $1.11, a 11.57% increase year-over-year.
- Edgewise Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.39.
- Edgewise Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$1.63.
- Edgewise Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.45.
- Edgewise Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$1.57.
- Edgewise Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$1.26.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.53 10-Q · filed 2026-08-06 | -$0.99 10-Q · filed 2026-08-06 | $0.10 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.46 10-Q · filed 2026-05-07 | $0.64 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.26 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.08 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | $1.11 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.73 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.39 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.63 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.39 10-Q · filed 2025-11-06 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.15 10-Q · filed 2025-11-06 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.34 10-Q · filed 2026-08-06 | -$0.77 10-Q · filed 2026-08-06 | $0.17 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.43 10-Q · filed 2026-05-07 | $0.56 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.20 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.13 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | $0.99 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.64 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.30 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.45 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.36 10-Q · filed 2025-11-06 | -$0.70 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.03 10-Q · filed 2025-11-06 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2024-06-30 | -$0.34 10-Q · filed 2025-08-07 | -$0.66 10-Q · filed 2025-08-07 | $0.12 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2024-03-31 | -$0.33 10-Q · filed 2025-05-08 | $0.54 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.22 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.08 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2023-12-31 | $1.08 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.69 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.36 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.57 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.41 10-Q · filed 2024-11-07 | -$0.74 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.10 10-Q · filed 2024-11-07 | -$1.41 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2023-06-30 | -$0.34 10-Q · filed 2024-08-08 | -$0.70 10-Q · filed 2024-08-08 | -$1.01 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.34 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2023-03-31 | -$0.36 10-Q · filed 2024-05-09 | -$0.67 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.00 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.33 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2022-12-31 | -$0.31 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$0.64 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$0.96 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$1.26 10-K · filed 2024-02-22 |
| 2022-09-30 | -$0.34 10-Q · filed 2023-11-09 | -$0.66 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.96 10-Q · filed 2023-11-09 | -$1.22 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$0.32 10-Q · filed 2023-08-10 | -$0.62 10-Q · filed 2023-08-10 | -$0.88 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.14 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-03-31 | -$0.30 10-Q · filed 2023-05-11 | -$0.55 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.82 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.03 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2021-12-31 | -$0.26 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$0.52 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$0.73 derived: net income ÷ weighted average shares · filed 2023-02-23 | -$1.14 10-K · filed 2023-02-23 |
| 2021-09-30 | -$0.26 10-Q · filed 2022-11-03 | -$0.47 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.90 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$0.21 10-Q · filed 2022-08-04 | -$0.67 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$4.37 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | -$23.17 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |